Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

May 5, 2026

mental-health

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

ONLY AVAILABLE IN PAID PLANS.

Originally reported by globenewswire. Read more

Source: https://www.globenewswire.com/news-release/2026/05/05/3287509/0/en/Eupraxia-Pharmaceuticals-Reports-EREFS-Data-from-its-Ongoing-Phase-1b-2a-RESOLVE-Trial-in-Eosinophilic-Esophagitis-at-Digestive-Disease-Week-DDW.html